Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.64 |
| ▸ | HTR2A | P28223 | 7/20 | 0.60 |
| ▸ | HTR1D | P28221 | 7/20 | 0.60 |
| ▸ | HTR1A | P08908 | 6/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.60 |
| ▸ | HTR1B | P28222 | 4/20 | 0.60 |
| ▸ | HTR2C | P28335 | 3/20 | 0.60 |
| ▸ | HTR7 | P34969 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HTR6 | P50406 | 2/20 | 0.60 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.60 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.60 |
| ▸ | HTR3B | O95264 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7494814 | 0.98 | SLC6A4 (0.63) | SLC6A4HTR2AHTR1DHTR1ATRPM8 | |
| SCHEMBL5234124 | 0.91 | SLC6A4 (0.69) | SLC6A4HTR1AMPO | |
| SCHEMBL4833994 | 0.90 | SLC6A4 (0.67) | SLC6A4HTR1AMPO | |
| SCHEMBL31573289 | 0.88 | HTR2A (0.65) | SLC6A4HTR2AHTR1DHTR1ATRPM8 | |
| SCHEMBL2539430 | 0.88 | HTR2A (0.65) | SLC6A4HTR2AHTR1DHTR1ATRPM8 | |
| SCHEMBL25244606 | 0.84 | SLC6A4 (0.64) | SLC6A4DRD3 | |
| SCHEMBL8136598 | 0.84 | SLC6A4 (0.64) | SLC6A4HTR2CCYP2D6DRD3 | |
| SCHEMBL12881233 | 0.84 | SLC6A4 (0.68) | SLC6A4HTR1ADRD3KMT2A | |
| SCHEMBL6108317 | 0.84 | SLC6A4 (0.64) | SLC6A4DRD3 | |
| SCHEMBL27402888 | 0.84 | SLC6A4 (0.64) | SLC6A4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140687-A1 | S1PR2 REGULATOR AND USE THEREOF | 北京昌平实验室 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255830-A | S1PR2 modulators and uses thereof | 北京昌平实验室 | 2024-06-28 | — | — | CN | disclosed |
| EP-2651887-B1 | N-(2-(5-substituted-1H-indol-3-yl)ethyl)biphenyl-4-carboxamide derivatives and related compounds as Tau-aggregation induced toxicity inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-9284271-B2 | Compounds for the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-03-15 | — | — | US | disclosed |
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SOLACE PHARMACEUTICALS UK LTD. (GB) | 2016-02-04 | — | — | US | disclosed |
| EP-1859798-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9169234-B2 | Sepiapterin reductase inhibitors for the treatment of pain | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-10-27 | — | — | US | disclosed |
| US-8921576-B2 | Spiroindoline compound, and medicinal agent comprising same | KOWA COMPANY, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | KOWA COMPANY, LTD (JP) | 2014-10-16 | — | — | US | disclosed |
| EP-2781521-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-1993021182-A1 | HETEROAROMATIC 5-HYDROXYTRYPTAMINE RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993020066-A1 | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
| US-5194440-A | Treatment for migraine; selective agonist | MERCK SHARP & DOHME LTD. (GB) | 1993-03-16 | — | — | US | disclosed |
| EP-0501568-A1 | Substituted cyclic sulphamide derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-09-02 | — | — | EP | disclosed |
| EP-0497512-A2 | Imidazole, triazole and tetrazole derivatives | MERCK SHARP & DOHME LTD. (GB) | 1992-08-05 | — | — | EP | disclosed |
| EP-0438230-A2 | Indole-substituted five-membered heteroaromatic compounds | MERCK SHARP & DOHME LTD. (GB) | 1991-07-24 | — | — | EP | disclosed |
| EP-0225726-B1 | INDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1991-04-17 | — | — | EP | disclosed |
| US-4833153-A | VASOCONSTRICTORS, MIGRAINES | GLAXO GROUP LIMITED (GB) | 1989-05-23 | — | — | US | disclosed |
| EP-0225726-A1 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1987-06-16 | — | — | EP | disclosed |
| US-4252803-A | HYPOTENSIVE AGENTS, ANALGESICS | GLAXO GROUP LIMITED (GB) | 1981-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031812-A1 | SEPIAPTERIN REDUCTASE INHIBITORS FOR THE TREATMENT OF PAIN | SPR, QDPR, SRR | SLC6A4 294/4885HTR2A 1809/4885HTR1D 1949/4885 |
| US-20140309207-A1 | NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME | GCKR, GCK, GALK1 | SLC6A4 2211/4885HTR2A 3442/4885HTR1D 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.